Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2010 May 10.
Published in final edited form as: J Proteome Res. 2009 Aug;8(8):4135–4143. doi: 10.1021/pr900248y

Identification of Astrocyte Secreted Proteins with a Combination of Shotgun Proteomics and Bioinformatics

James A Dowell 1, Jeffrey A Johnson 1,3,4,5, Lingjun Li 1,2,4,5,*
PMCID: PMC2866504  NIHMSID: NIHMS189651  PMID: 19469553

Abstract

Astrocytes are important regulators of normal brain function in mammals, including roles in synaptic signaling, synapse formation, and neuronal health and survival. Many of these functions are executed via secreted proteins. In order to analyze the astrocyte secretome, a combination of shotgun proteomics and bioinformatics was employed to analyze conditioned media from primary murine astrocyte cultures. Both two- and one-dimensional LC-MS/MS were used to analyze astrocyte secreted proteins, resulting in the identification of over 420 proteins. In order to refine our results, the intracellular protein contaminants were removed in silico using a cytoplasmic control. In additional rounds of refinement, putative secreted proteins were subjected to analysis by SignalP, SecretomeP, and gene ontology analysis, yielding a refined list of 187 secreted proteins. In conclusion, the use of shotgun proteomics combined with multiple rounds of data refinement produced a high quality catalog of astrocyte secreted proteins.

Introduction

Astrocytes are the most abundant cells in the human brain and play important roles in the central nervous system (CNS), including the regulation of extracellular glutamate, the coordination of synapse formation, and the maintenance of neuronal health.1 They perform many of their physiological functions via secreted proteins, including the regulation of synapse formation by thrombospondins,2 the promotion of axonal regeneration by extracellular metallothionein,3 and the prevention of neuronal apoptosis by transforming growth factor-β (TGF- β).4 A large number of bioactive proteins have been identified in astrocyte conditioned media, including trophic factors, cytokines, chemokines, proteases, and protease inhibitors.58

Astrocytes act as the sentinels of the brain and react to neuronal stress or injury by providing neuronal metabolic and trophic support.911 Nerve growth factor (NGF), brain derived neurotrophic factor (BDNF), and neurotrophin-3 (NT-3) are all expressed in astrocytes1215 and are induced during reactive astrogliosis.16, 17 The astrocytic expression of members of the transforming growth factor-β (TGF-β) super family, including glial derived neurotrophic factor (GDNF) and TGF- β, and members of the fibroblast growth factor family, including fibroblast growth factor-2 and -1 (FGF-1 and -2), are also induced upon reactive astrogliosis.1823

In addition to trophic factors, astrocytes release cytokines in response to brain injury and neurodegenerative disease. A number of pro-inflammatory cytokines are induced in reactive astrogliosis, including tumor necrosis factor-β, IL-6, and IL-1β.2326 Among the anti-inflammatory cytokines, IL-4 and IL-10 are induced in astrocytes during multiple sclerosis (MS) pathogenesis.27 Additionally, members of the cysteine-cysteine (CC) family of chemokines, including macrophage inflammatory protein-1 alpha (MIP-1α), regulated upon activation, normal T cell expressed and secreted (RANTES), and monocyte chemotactic protein-1, -2, and -3 (MIP-1, -2, -3), are induced during reactive astrogliosis in MS.28

Beyond their role in maintaining neuronal health and survival, astrocytes also regulate synapse formation and elimination via secreted proteins. Retinal ganglion cells (RGCs) cultured with astrocytes or astrocyte conditioned media (ACM) form substantially more synapses than RGCs cultured alone in serum-free media.29, 30 Recently, astrocyte-derived thrombospondins (TSPs), which are large extracellular matrix proteins,31 were found to significantly modulate synapse formation in RGCs.2 Synapse elimination also seems to be under the control of astrocyte secreted factors. In an attempt to elucidate the mechanisms of synapse elimination in the developing eye, Barres and co-workers examined the gene expression changes in RGCs co-cultured with immature astrocytes.32 The immature astrocytes induced the expression of the complement cascade protein C1q almost 30-fold in the co-cultured RGCs. However, the astrocyte secreted factor responsible for the C1q induction remains unidentified.

In order to better understand the complex extracellular signaling mediated by astrocytes, a catalog of astrocyte secreted proteins is an essential starting point for further research. Four studies have attempted a global strategy to identify astrocyte secreted proteins.58 The first two studies employed two-dimensional gel electrophoresis followed by matrix-assisted laser desorption/ionization mass spectrometry (MALDI-MS) for protein identification.5, 6 However, both of these studies yielded a relatively low number of total protein identifications (less than 40 total proteins) and many of the identified proteins are not known to be secreted. Two more recent studies employed shotgun proteomics with high performance liquid chromatography coupled to electrospray mass spectrometry (LC-MS/MS); a methodology which yielded a substantially larger list of putative secreted proteins.7, 8 One study investigated secreted proteomic changes in astrocytes exposed to inflammatory cytokines.8 The other report focused on the identifications of proteins involved in neuronal development induced by astrocyte cholinergic stimulation.7 In contrast to these studies, we utilized a cytoplasmic control in conjunction with quantitative proteomics to identify cytoplasmic protein contaminants which are not actively secreted from cells. In addition, we applied a two-dimensional LC-MS/MS methodology to increase proteome coverage and multiple rounds of data refinement using gene ontolotgy analysis, SignalP and SecretomeP to increase the confident identification of secreted proteins.

There are numerous technical challenges in developing effective tools for global secretome analysis. In regards to cell culture technique, the optimization of protein-free media conditions, including length of serum-free incubation and cell washing procedures, is important to minimize cell death. Downstream sample processing and analytical methods are equally important and require rigorous optimization due to the low concentration of many trophic factors and cytokines which are present at low ng/ml concentrations.33

A number of studies have analyzed the secretomes of various cell types, including endothelial,34 myeloid,33 adipocytes,35, 36, microglia,37 retinal pigment epithelial cells,38 and various cancer cell lines.3941 Many of these studies have developed novel techniques to addres the issues mentioned above, including two-dimensional LC-MS/MS shotgun proteomics.35, 3941 Each study employed cell washing techniques to remove serum proteins, however, some groups only used a single wash 41 while other groups found a triple wash to be optimal.34 As for protein precipitation and extraction, two studies found a hydrophobic resin extraction to improve recovery39, 40 while another study found the optimal precipitation conditions to be trichloroacetic acid (TCA) precipitation with sodium lauroyl sarcosinate (NLS).33 Finally, the use of a cytoplasmic extract or whole cell lysate to control for intracellular protein contamination is an effective way to more confidently identify secreted proteins.33, 42 In the current study, we optimized washing procedures, incubation times, employed a cytoplasmic control, and used both 1D and 2D LC-MS/MS to maximize the identification of astrocyte secreted proteins.

Experimental Method

Experimental Overview

Proteins secreted from primary astrocyte cultures were analyzed by LC-MS/MS. A cytoplasmic extract was used as a control and also analyzed by LC-MS/MS. Two different LC-MS/MS methods were used to analyze the secreted proteins: the first was a standard 1D LC-MS/MS experiment (3 technical replicates per n; n=2 biological replicates); the second was a 2D LC-MS/MS experiment in which the proteins were fractionated by off-line reverse phase high performance liquid chromatography (RPLC), the resulting fractions collected, trypsinated, and subjected to LC-MS/MS (no technical replicates; n=2 biological replicates).

Materials for Cell Culture

The Hank's balanced salt solution (HBSS), Dulbecco's modified Eagle's medium (DMEM), Neurobasal medium (NB), fetal bovine serum (FBS), penicillin/streptomyocin were obtained from Invitrogen (Carlsbad, CA). The sodium bicarbonate, HEPES, trypsin, DNase, and 70-μm cell strainer were obtained from Sigma (St. Louis, MO). 25 cm2 culture flasks (T-25) were obtained from Nunc (Naperville, IL).

The culture medium (DMEM+FBS) consisted of Dulbecco's modified Eagle's medium (DMEM) with 4 mM glutamine and supplemented with: 1.2 mg/ml sodium bicarbonate, 3.6 mg/ml HEPES, 10% fetal bovine serum (FBS), penicillin/streptomyocin at 100 IU/ml and 100 μg/ml, respectively.

Primary Astrocyte Culture

Primary astrocyte cultures were prepared from postnatal day 1 (P1) mice as previously described with minor modifications.43 Briefly, the cerebral cortices from individual P1 pups were removed, placed in ice-cold HBSS, minced with a scalpel blade, and then transferred to a tube with 2 ml of 0.25% trypsin at 37 °C. After 25 minutes, 1 ml of culture medium (DMEM+FBS) was added to deactivate the trypsin. DNase was added to a final concentration of 0.05 mg/ml and then the tube was spun at 300 g for 5 minutes. The supernatant was removed and the tissue pellet was re-suspended in 1 ml of fresh DMEM+FBS. After triturating 15–20 times with a 1 ml pipette, 4 ml of DMEM+FBS was added to the disassociated cells and then the suspension was filtered through a 70 μm cell strainer. The cells from a single pup were plated onto an uncoated, plastic T-25 flask. The DMEM+FBS was changed after the first day and then every 3 days thereafter.

Preparation of Astrocyte Conditioned Medium

After the astrocytes reached confluency (Day 7–8), the flasks were placed on a rotary shaker (200 rpm) for 24 hours. After shaking, the DMEM+FBS was removed and discarded (shaking removes the majority of microglia, oligodendrocytes, and neurons). The astrocytes were then washed three times with Hank's Balance Salt Solution (HBSS) and then 5 ml of neurobasal (NB) medium was added. After 24 hours, the astrocyte conditioned medium (ACM) was removed with a pipette and centrifuged at 3,000 g for 25 minutes to remove cells and debris. The conditioned medium was stored at −80 °C until processed. After thawing, the conditioned medium was concentrated 20–40X with a 3 kDa MWCO tube (Amicon,15mL) from Thermo Fisher Scientific (Waltham, MA) at 3,000 g in a refrigerated centrifuge (4 °C). Total protein concentration was determined by Bradford assay. Alternatively, the conditioned medium was precipitated using trichloroacetic acid (TCA) with the carrier sodium lauroyl sarcosinate (NLS) as performed by Chevallet and co-workers.33 Briefly, NLS was added to each sample to a concentration of 0.1% followed by the addition of TCA to the concentration of 10%. Proteins were allowed to precipitate for 2 hours on ice, spun at 10,000 g for 15 minutes, and the supernatant discarded. The proteins pellets were washed twice with tetrahydrofuran (THF) and then re-suspended in 6 M urea.

Preparation of Cytoplasmic Protein Extract

After removal of the astrocyte conditioned media, the confluent astrocyte layer was washed with HBSS. The cells were then scraped from the flask in 1 ml of PBS and pipetted into a Dounce glass-glass homogenizer on ice. After 10 strokes with the Dounce homogenizer, the cell extract was spun at 18,000 g for 30 minutes in a refrigerated centrifuge (4 °C). The supernatant (cytoplasmic protein extract) was decanted and stored at −80 °C until processed.

Protein Digestion

Protein samples were diluted into 6 M urea/50 mM ammonium bicarbonate buffer (pH 8). Cysteinyl disulfides were reduced by the addition of 2 mM Tris[2-carboxyethyl] phosphine (TCEP) from Sigma for 30 minutes at 37 °C. Reduced disulfides were then alkylated by the addition of 10 mM iodoacetamide from Sigma (IAA) for 30 minutes in the dark. The urea was then diluted to <1 M with 50 mM ammonium bicarbonate and the pH was measured and adjusted to pH 7.8. Trypsin from Promega (Madison, WI) was added at a 1:20 weight-to-weight ratio and incubated for 18 hours at 37°C. After digestion, the solvent was removed by vacuum centrifugation.

Off-line Protein Separation via Reversed Phase Liquid Chromatography (RPLC)

Forty μg of undigested protein extract in 100 μl of water was delivered to a macroporous mRP-C18 column (2.1 × 75mm, 5μm) from Agilent (Santa Clara, CA) via a Rainin (Oakland, CA) Dynamax HPLC equipped with a 100 μl sample loop, binary pump, UV detector, and fraction collector. To increase recovery and decrease protein adsorption, the column was heated to 80 °C throughout the separation. Proteins were eluted with a linear gradient of 0.1% TFA in acetonitrile (HPLC Buffer B) from 15–55% over 60 minutes (HPLC Buffer A was 0.1% TFA in water). Fractions were collected every 5 minutes for a total of 12 fractions. Each fraction was vacuum-centrifuged to ~50 μl and then diluted to 80% acetonitrile/20% 50 mM NH4CO3 and digested according to the Protein Digestion procedure. The digested fractions were reconstituted in 20μL of 0.1% FA; 10 μl of each reconstituted fraction was analyzed by LC-MS/MS.

LC-MS/MS

Using a nanoflow HPLC from Eskigent, tryptic peptides were delivered to a trap column (Zorbax 300SB-C18, 5μm, 0.3 × 50 mm, Agilent, Santa Clara, CA) via an isocratic flow of 0.1% formic acid in water (LC Buffer A) at a rate of 5 μl/min for 2 min. The flow rate was then reduced to 300 nl/min, and the peptides were flushed onto an in-house packed capillary column (Magic C18, 5μm, 75 μm × 150 mm) and eluted via a 5–35% linear gradient of 0.1% formic acid in acetonitrile (LC Buffer B) over 120 minutes into a nanoelectrospray ionization (nESI) linear ion trap mass spectrometer (LTQ) from Thermo Fisher Scientific. The MS survey scan was performed in positive ion mode from m/z 400 to 2000, followed by data-dependent MS/MS acquisition up to m/z 2000. The signal threshold for switching from the survey scan to MS/MS was set at 3000. Normalized collision energy was set at 35; capillary voltage, 3000 V; capillary temperature, 200 °C. Dynamic exclusion was activated with the following parameters: repeat count was 1, repeat duration was 60 s, and the exclusion duration was 60 s.

Database Search

Bioworks from Thermo-Electron (version 3.0) was used to convert the .RAW files generated during the LC-MS/MS runs into .dta text files for database searching (see Figure 1). The .dta files from each sample were then combined into a single file using the OMSSA search engine (version 2.1.1) from the National Center for Biotechnology Information (NCBI). For the 1D LC-MS/MS samples, the technical replicate .dta files were all combined into a single file for database searching. Using OMSSA, the combined .dta files were searched against the Swiss-Prot database, with the following parameters: taxonomy was limited to mus musculus, parent mass tolerance was 2.0 Da, fragment mass tolerance was 0.8 Da, a maximum of two missed cleavages was allowed, and the protein expectation value (log E) was required to be <−1.3. Carbamidomethylation at cysteine residues was set as a fixed modification and oxidation of methionine was set as a variable modification. After database searching, proteins were filtered by Top Hit per Spectrum Only in OMSSA browser. The false discovery rate (FDR) was determined using the X!Tandem search engine (version 2.2.1).

Figure 1.

Figure 1

Data Analysis Overview. Thermo-Finnigan LTQ .RAW files were processed into .dta files using Thermo-Finnigan Bioworks. The individual .dta files were concatenated using NCBI OMSSA and searched against the Swiss-Prot database. The search results, including the spectral counts for each protein, were exported to MS Excel. Each run was normalized against the cytoplasmic control based on the total spectral counts and zero calls were converted to 0.5. A Gene Ontology (GO) Analysis was performed to determine protein secretion. Separately, the Average Fold Enrichment (AFE) was calculated for each protein and those exhibiting at least a 2-fold enrichment versus the cytoplasmic control were then subjected to SecretomeP analysis. Finally, the GO and SecretomeP results were combined.

Quantitative Analysis by Spectral Counting

From the OMSSA browser, the spectral counts for each protein, were exported to Microsoft Excel. Each protein was required to have at least two total spectral counts from the summation of the four biological replicates. To correct for differences in sample preparation and run-to-run instrument variation, the total spectral counts for individual runs were normalized to the cytoplasmic control. All zero counts were converted to 0.5 to avoid dividing by zero when calculating the enrichment factor.

Average Fold Enrichment (AFE)

After normalization, the spectral counts for each protein in a media run were compared against the spectral counts for the same protein in the cytoplasmic control. From this comparison, a fold-enrichment was determined which reflects the relative enrichment of a protein in the media versus the cytoplasmic control. The average fold enrichment (AFE) analysis across all runs was calculated and the identified proteins were then filtered based on this value. To be considered for further analysis, each protein had to be enriched by at least 2-fold relative to the cytoplasmic control.

Gene Ontology Analysis, ExPASy, SignalP, and SecretomeP

Using the online version of DAVID Bioinformatics Resources 2008 from the NIAID (http://david.abcc.ncifcrf.gov/),44 all the identified proteins from the astrocyte conditioned media were analyzed for an extracellular localization. A functional annotation analysis was performed with the gene ontology tool (GOTERM_CC_ALL) using the UniProt Accession numbers for all identified proteins and extracellular proteins were so noted in GO column (see Table 1). Additionally, proteins passing the 2-fold AFE cut-off were searched against the Swiss-Prot/TrEMBL annotated database using the online ExPASy interface (http://www.expasy.ch/). Proteins that were known to be membrane proteins, secreted proteins, or had a signal peptide were so noted in the SecP column (see Table 1). If, however, a protein yielded a two-fold enrichment factor but was not reported to be a secreted protein, then SignalP (http://www.cbs.dtu.dk/services/SignalP/) and SecretomeP (http://www.cbs.dtu.dk/services/SecretomeP) were employed to determine if the protein might be secreted.45 A SecretomeP score above 0.5 indicates a high probability of being secreted via a non-classical pathway. In order to be considered secreted, a protein had to exhibit a 2-fold enrichment factor and be known to be secreted or predicted to be secreted by SignalP or SecretomeP (see Figure 1).

Table 1.

Astrocyte secreted proteins identified by LC-MS/MS and bioinformatics tools

Protein Name Acc# SecP GO SUM SC AFE
SPARC P07214 Yes E 447 224
Fibronectin precursor (FN) P11276 Yes E 330 165
Pigment epithelium-derived factor precursor (PEDF) P97298 Yes E 298 149
Cystatin-C P21460 Yes E 274 137
Complement C3 P01027 Yes E 251 125
Clusterin Q06890 Yes E 241 121
Collagen alpha-1(I) P11087 Yes E 188 94
Cadherin-2 P15116 Yes E 186 93
Alpha-2-macroglobulin-P Q6GQT1 Yes 160 80
Follistatin-related protein 1 Q62356 Yes E 147 74
Insulin-like growth factor-binding protein 5 Q07079 Yes E 118 59
Secretogranin-3 P47867 Yes E 110 55
Collagen alpha-2(V) Q3U962 Yes E 103 52
Nucleobindin-1 Q02819 signal 101 50
Collagen alpha-2(I) Q01149 Yes E 83 42
Calumenin O35887 signal 83 41
Insulin-like growth factor-binding protein 2 P47877 Yes E 469 39
Neurocan core protein P55066 Yes E 73 36
Dickkopf-related protein 3 Q9QUN9 Yes E 67 33
ProSAAS Q9QXV0 Yes E 62 31
Latent-transforming growth factor beta-binding protein 2 O08999 Yes 44 22
Nidogen-2 O88322 Yes E 43 21
Chitinase-3-like protein 1 Q61362 Yes E 41 21
Apolipoprotein E P08226 Yes E 38 19
Neuroendocrine protein 7B2 P12961 Yes E 37 19
Cathepsin D precursor P18242 Yes 33 17
Macrophage colony-stimulating factor 1 P07141 Yes E 32 16
Insulin-like growth factor-binding protein 7 Q61581 Yes E 31 16
Serine protease inhibitor A3N Q91WP6 Yes E 29 14
Proheparin-binding EGF-like growth factor Q06186 Yes E 28 14
Extracellular matrix protein 1 Q61508 Yes E 28 14
Mimecan Q62000 Yes E 27 13
Phospholipid transfer protein P55065 Yes E 26 13
Dystroglycan Q62165 signal E 24 12
Esophageal cancer-related gene 4 Q99LS0 Yes E 24 12
SPARC-like protein 1 P70663 Yes E 23 12
Biglycan P28653 Yes E 21 10
Insulin-like growth factor-binding protein 3 P47878 Yes E 21 10
Protein CYR61 P18406 Yes E 20 10
Granulins P28798 Yes E 19 10
Fibulin-5 Q9WVH9 Yes E 19 10
Collagen alpha-1(IV) P02463 Yes E 18 9
WNT1-inducible-signaling pathway protein 2 Q9Z0G4 Yes E 17 9
Carboxypeptidase E Q00493 Yes E 17 9
Lysosome-associated membrane glycoprotein 2 P17047 Yes E 17 9
Extracellular superoxide dismutase O09164 Yes 17 9
Complement C4-B P01029 Yes E 16 8
Sulfated 50 kDa glycoprotein Q02596 Yes E 15 7
Cathepsin L1 P06797 Yes E 14 7
Transcobalamin-2 O88968 Yes E 14 7
Plasma protease C1 inhibitor P97290 Yes E 14 7
L-lactate dehydrogenase A P06151 0.568 54 7
Biotinidase Q8CIF4 Yes 13 7
Insulin-like growth factor-binding protein 4 P47879 Yes E 13 6
Tenascin Q80YX1 Yes E 13 6
Fibromodulin P50608 Yes E 13 6
Epididymal secretory protein E1 Q9Z0J0 Yes E 13 6
Inter-alpha-trypsin inhibitor heavy chain H2 Q61703 Yes E 12 6
Elastin P54320 Yes E 12 6
Platelet-activating factor acetylhydrolase Q60963 Yes E 11 6
Thymosin beta-4 P20065 0.864 13 6
Transgelin P37804 0.645 24 6
Brain acid soluble protein 1 Q91XV3 membrane 12 6
Serine protease inhibitor A3G Q5I2A0 Yes 11 6
Metalloproteinase inhibitor 2 P25785 Yes E 11 5
Ribonuclease pancreatic P00683 Yes E 10 5
Calsyntenin-1 Q9EPL2 Yes E 10 5
EGF-containing fibulin-like extracellular matrix protein 2 Q9WVJ9 Yes E 10 5
Calsequestrin-1 O09165 signal E 9 5
Nuclease sensitive element-binding protein 1 P62960 0.73 11 5
Amyloid beta A4 protein P12023 membrane 10 5
Phosphoinositide-3-kinase-interacting protein 1 Q7TMJ8 membrane 10 5
Stathmin P54227 0.725 9 5
Serine protease HTRA1 Q9R118 Yes E 9 4
Osteopontin P10923 Yes E 8 4
Insulin-like growth factor-binding protein 1 Q80W15 Yes E 8 4
Collagen alpha-1(II) P28481 Yes E 8 4
FXYD domain-containing ion transport regulator 6 Q9D164 membrane E 8 4
Procollagen-lysine,2-oxoglutarate 5-dioxygenase 2 Q9R0B9 Yes E 8 4
Transthyretin P07309 Yes E 7 4
Spondin-1 Q8VCC9 Yes E 7 4
Ezrin P26040 0.585 17 4
Myristoylated alanine-rich C-kinase substrate P26645 membrane 8 4
Tubulin polymerization-promoting protein family member 3 Q9CRB6 0.518 8 4
Apolipoprotein A-I-binding protein Q8K4Z3 Yes 8 4
Scotin Q9D7I0 membrane 8 4
Thymosin beta-10 Q6ZWY8 0.752 8 4
Serine protease inhibitor A3M Q03734 Yes 7 4
Prostaglandin-H2 D-isomerase O09114 Yes E 7 3
Reticulocalbin-1 Q05186 signal E 7 3
Connective tissue growth factor P29268 Yes E 7 3
Serpin H1 P19324 Yes E 7 3
Gelsolin P13020 Yes E 6 3
Palmitoyl-protein thioesterase 1 O88531 Yes E 6 3
Collagen alpha-1(V) O88207 Yes E 6 3
Antithrombin-III P32261 Yes E 6 3
Platelet-derived growth factor A chain P20033 Yes E 6 3
Hepatoma-derived growth factor P51859 Yes E 6 3
Collagen alpha-1(XI) Q61245 Yes E 5 3
Peptidyl-prolyl cis-trans isomerase B P24369 Yes E 5 3
Neuroblastoma suppressor of tumorigenicity 1 Q61477 Yes E 5 3
45 kDa calcium-binding protein Q61112 0.692 E 5 3
Cathepsin B P10605 Yes 56 3
Acyltransferase-like 1-A Q8BYI6 membrane 7 3
Coiled-coil domain-containing protein 80 Q8R2G6 Yes 7 3
Serine protease inhibitor A3C P29621 Yes 6 3
Serine protease inhibitor A3F Q80X76 Yes 6 3
Serine protease inhibitor A3K P07759 Yes 6 3
Metallothionein-3 P28184 Yes 6 3
Parathymosin Q9D0J8 0.673 6 3
CD44 antigen P15379 Yes 6 3
Y-box-binding protein 2 Q9Z2C8 0.71 6 3
DNA-binding protein A Q9JKB3 0.676 6 3
Moesin P26041 0.558 12 3
Glutathione S-transferase P 1 P19157 Yes 5 3
Glutathione S-transferase P 2 P46425 Yes 5 3
PRKC apoptosis WT1 regulator protein Q925B0 0.799 5 3
Metallothionein-2 P02798 Yes 5 3
Ubiquitin-conjugating enzyme E2 L3 P68037 0.582 5 3
Metalloproteinase inhibitor 1 P12032 Yes E 5 2
72 kDa type IV collagenase P33434 Yes E 5 2
N(4)-(beta-N-acetylglucosaminyl)-L-asparaginase Q64191 signal E 5 2
Microfibril-associated glycoprotein 4 Q9D1H9 Yes E 5 2
FMRFamide-related peptides Q9ESQ8 Yes E 5 2
Fibulin-1 Q08879 Yes E 5 2
Delta-like protein Q09163 membrane E 5 2
Chordin-like protein 1 Q920C1 Yes E 4 2
Lysyl oxidase homolog 3 Q9Z175 Yes E 4 2
Galectin-3 P16110 Yes E 4 2
Cell adhesion molecule 4 Q8R464 membrane E 4 2
Procollagen-lysine,2-oxoglutarate 5-dioxygenase 1 Q9R0E2 Yes E 4 2
Amyloid-like protein 2 Q06335 membrane E 4 2
Cathepsin Z Q9WUU7 Yes E 4 2
Collagen alpha-2(IV) P08122 Yes E 4 2
Glucose-6-phosphate isomerase P06745 Yes E 21 2
Peroxiredoxin-4 O08807 Yes E 3 2
Tyrosine-protein phosphatase non-receptor type substrate 1 P97797 Yes E 3 2
Gamma-glutamyl hydrolase Q9Z0L8 Yes E 3 2
Fractalkine O35188 Yes E 3 2
Glypican-4 P51655 Yes E 3 2
Prolargin Q9JK53 Yes E 3 2
WAP four-disulfide core domain protein 2 Q9DAU7 Yes E 3 2
Thioredoxin domain-containing protein 4 Q9D1Q6 signal E 3 2
Brevican core protein Q61361 Yes E 3 2
Inter-alpha-trypsin inhibitor heavy chain H3 Q61704 Yes E 3 2
Translationally-controlled tumor protein P63028 Yes E 3 2
Beta-hexosaminidase beta chain P20060 signal 5 2
Legumain O89017 signal 5 2
Keratinocytes-associated transmembrane protein 2 Q8K201 membrane 5 2
Polyadenylate-binding protein-interacting protein 2 Q9D6V8 0.816 5 2
Sterile alpha motif domain-containing protein 3 Q8C4H2 0.594 4 2
Lysosomal protective protein P16675 signal 4 2
Ubiquitin P62991 0.693 84 2
Acid ceramidase Q9WV54 0.781 4 2
Drebrin Q9QXS6 0.72 4 2
Acylphosphatase-2 P56375 0.712 4 2
Plasma glutamate carboxypeptidase Q9WVJ3 Yes 4 2
Protein DJ-1 Q99LX0 0.537 4 2
Chromobox protein homolog 3 P23198 0.836 4 2
Putative RNA-binding protein 3 O89086 0.745 4 2
Eukaryotic initiation factor 4A-III Q91VC3 0.634 4 2
Eukaryotic initiation factor 4A-I P60843 0.631 4 2
Stathmin-2 P55821 membrane 4 2
Syndecan-4 O35988 membrane 4 2
PDZ and LIM domain protein 5 Q8CI51 0.522 4 2
Profilin-1 P62962 0.56 16 2
Secernin-1 Q9CZC8 0.516 14 2
Protein kinase C and casein kinase substrate Q9WVE8 0.608 4 2
Isocitrate dehydrogenase O88844 0.576 4 2
Chloride intracellular channel protein 4 Q9QYB1 0.563 4 2
Sulfhydryl oxidase 1 Q8BND5 Yes 4 2
BolA-like protein 1 Q9D8S9 0.864 3 2
LIM and SH3 domain protein 1 Q61792 0.722 3 2
3'(2'),5'-bisphosphate nucleotidase 1 Q9Z0S1 0.652 3 2
Probable ATP-dependent RNA helicase DDX56 Q9D0R4 0.534 3 2
SH3 domain-binding glutamic acid-rich-like protein 3 Q91VW3 0.758 3 2
Corneodesmosin Q7TPC1 Yes 3 2
Placenta-specific protein 9 Q8K262 Yes 3 2
Methylcrotonoyl-CoA carboxylase beta chain Q3ULD5 signal 3 2
Sortilin-related receptor O88307 membrane 3 2
Chromobox protein homolog 1 P83917 0.872 3 2
Probable ATP-dependent RNA helicase DDX5 Q61656 0.502 3 2
Ubiquitin carboxyl-terminal hydrolase isozyme L1 Q9R0P9 0.54 6 2
Thioredoxin domain-containing protein 16 Q7TN22 Yes 3 2
Cysteine-rich protein 2 Q9DCT8 0.807 3 2
WD repeat-containing protein 1 O88342 0.518 3 2
Opioid growth factor receptor Q99PG2 membrane 3 2

Note: Protein Name is the Swiss-Prot name for the identified protein. Acc # is the Swiss-Prot accession number for the identified protein. Sum SC is the total normalized spectral counts from all LC-MS/MS runs. The SecP column indicates the results from the ExPasy, SignalP, and SecretomeP analysis: `Yes' indicates known secretion from Swiss-Prot database; `signal' indicates a known or predicted signal peptide from the Swiss-Prot database or SignalP analysis;,a number in the SecP column indicates the numerical score returned by SecretomeP (greater than 0.5 indicates high probability of non-classical secretion). `E' in the GO column indicates an extracellular protein as determined by Gene Ontology Analysis.

Results and Discussion

Sample Preparation

Initially different sample preparation techniques were examined in order to optimize protein recovery and minimize protein contamination from both serum and dead or dying cells. In order to remove serum proteins, we examined different cell rinsing strategies, including the use of phosphate buffered saline (PBS) or Hank's Balance Salt Solution (HBSS). The use of PBS for rinsing resulted in reactive astrogliosis (data not shown). This astrogliosis subsided after a few hours after rinsing; however, reactive astrocytes can exhibit different protein secretion profiles than resting astrocytes10, 11 so it was deemed prudent not to use PBS as a rinsing solution. Rinsing with HBSS did not result in astrogliosis and so all rinses were performed with HBSS. The number of times the cells were rinsed was also optimized to strike a balance between serum protein removal and cell stress. Three rinsings was found to remove the majority of serum proteins, as determined by the reduction of serum proteins in the LC-MS/MS analysis, while minimizing cell stress as determined by visual inspection via microscope (data not shown). Additionally, different protein concentration methods were also used, including TCA-NLS precipitation and ultrafiltration using Amicon molecular weight cut-off devices. The TCA-NLS method resulted in significant sample loss while ultrafiltration yielded good sample recovery (data not shown). Ultrafiltration was used for all experiments included in this study.

False Discovery Rate, Spectral Counting and Average Fold Enrichment (AFE)

Using the X!Tandem search engine, the false discovery rate was estimated to be 0.71%, the p-score was 75, and the valid log E cut-off <−1.3. All of the 187 proteins reported in Table 1 were above this log E cut-off. As an additional requirement for positive identification, each protein was required to have at least two total spectral counts from the summation of all four biological replicates.

By comparing the normalized spectral counts for each protein from the astrocyte conditioned media to the cytoplasmic control, we were able to determine the average fold enrichment (AFE) factor of each protein. If the protein was enriched by at least 2-fold, it was then subjected to bioinformatics analysis to determine possible secretion or residence in the extracellular compartment.

Bioinformatics Analysis

Proteins which passed the AFE filter were subjected to analysis by database search, SignalP, and SecretomeP. Employing the online ExPASy interface, the subcellular location of each protein was determined from the annotations in the Prot/TrEMBL database. Proteins that were annotated as secreted, possessing a signal peptide, or were membrane bound were included in Table 1. The remaining proteins were then subjected to SignalP and SecretomeP analysis. Those proteins which were predicted to have signal peptide by SignalP or had a significant SecretomeP score (0.5 or higher) were included in Table 1. A Gene Ontology (GO) analysis was performed on all of the identified proteins from the astrocyte conditioned media as a confirmation of the results from the AFE and SignalP/SecretomeP analysis.

Identified Proteins and Data Analysis

A total of 423 proteins were identified from all the 2D- and 1D-LC-MS/MS analyses of astrocyte conditioned media. Figure 2 shows an example of a base peak chromatogram from the LC-MS/MS analysis of astrocyte conditioned media (see Fig. 2A) and a representative tandem MS/MS spectrum of a tryptic peptide (YIALEEWAGCFGIK) from secreted protein acidic and rich in cysteine (SPARC) (see Fig. 2B). A GO analysis of this data set yielded 148 proteins that were localized to the extracellular region (see Figure 3). Separately, the application of the AFE filter with a 2-fold cut-off returned 262 proteins. This protein list was refined with a manual search of the Swiss-Prot database and analysis by SignalP and SecretomeP, yielding 187 proteins passing both the AFE and ExPASy/SignalP/SecretomeP filters (see Figure 3 and Table 2). When a GO was performed on the same AFE filtered proteins, only 106 were identified as being extracellular.

Figure 2.

Figure 2

Example LTQ MS and MS/MS spectra. (A) Base peak chromatogram from a 1D LCMS/MS of a tryptic digest of astroctye secreted proteins. (B) MS/MS spectrum of tryptic peptide (YIALEEWAGCFGIK, m/z 828.92+) from SPARC (Secreted protein acidic and rich in cysteine).

Figure 3.

Figure 3

Venn diagram of OMSSA protein identifications from astrocyte conditioned media. Total proteins were filtered by Average Fold Enrichment (AFE), SecretomeP (SecP), and Gene Ontology Analysis (GO).

Table 2.

Summary of identified proteins passing successive filtering by Average Fold Enrichment (AFE) and SecretomeP (SecP).

Total number of proteins Number of extracellular proteinsA Number of secreted proteinsB
Media 423 148 112

AFE2 262 106 88
AFE2 +SecP 187 106 88

AFE3 167 80 71
AFE3+SecP 123 80 71

AFE2 and AFE3 are a two- and three-fold cutoff, respectively.

(A)

Number of proteins identified as residing in the `Extracellular Region' by Gene Ontology Analysis.

(B)

Number of proteins identified as being `Secreted' by Gene Ontology Analysis.

The use of multiple data refinement tools, including GO, AFE, and SignalP/SecretomeP, ensures the confident and comprehensive identification of secreted proteins. These tools are highly complementary and their combined use yields high quality data sets. However, each tool has its advantages and disadvantages. The GO analysis is a very mature tool and yields a large amount of important data with minimal effort. The direct application of a GO analysis to the raw protein data yielded a total of 148 proteins identified as secreted (see Table 2). However, a manual examination of the Swiss-Prot/TrEMBL database yielded a number of secreted proteins which were not identified as such in the GO search. Out of the 262 proteins passing the AFE filter, 144 were identified as extracellular by a manual ExPASy database search while the GO analysis only yielded 106 extracellular proteins—a difference of over 25%. This difference is largely the result of some proteins lacking a GO annotation in the Swiss-Prot database. While a manual examination of the Swiss-Prot database yields a more comprehensive list of secreted proteins, this method is time consuming and cumbersome. A first pass filtering of the data through a GO analysis followed by a targeted manual database search is the most comprehensive and practical way of combining these tools. In addition, the use of AFE filtering and SignalP/SecretomeP expands the number of putative secreted proteins beyond those annotated in the Swiss-Prot database while maintaining a high degree of confidence in their identities as secreted proteins.

As mentioned in the introduction, two earlier studies employed two-dimensional gel electrophoresis to examine astrocyte secreted proteins, resulting in 40 identified proteins.5, 6 Out of the 40 proteins identified in these studies, 38 were identified in the current study; however, out of these 38 proteins only 14 passed the criteria for enrichment and predictive secretion. Furthermore, these 14 proteins were all brefeldin A sensitive, indicating a vesicular pathway of secretion.5 Based on our results, it would seem that only the brefeldin A sensitive proteins are actively secreted and the remaining proteins identified as `secreted' are most likely cytoplasmic proteins released from dead or dying cells.

Two more recent studies have used shotgun proteomics to identify proteins secreted by astrocytes.7, 8 In the study by Moore and co-workers, gene ontology assignments were used to identify a total of 133 putative secreted proteins from rat primary astrocytes. When the list of secreted proteins from this study is compared against our list of secreted proteins, our study identified 85 out of the 133 proteins identified by Moore and co-workers as secreted, more than a 63% overlap in identifications. However, out of the 85 identifications common to both studies, 16 did not pass our AFE filter and 5 out of those 16 were enriched in the cytoplasmic control, indicating the possibility that these proteins are cytoplasmic contaminants.

Many of the differences between the two studies can be attributed to the differences in naming convention and gene IDs between the rat and mouse protein databases which results in errors in assessing protein overlap between the two studies. Additionally, differences in analytical strategy and instrumentation, i.e. the exclusive use of 1D LC-MS/MS by Moore and co-workers versus the use of both 1D and 2D LC-MS/MS in our study, and differences in the bioinformatics tools used to analyze the data set, i.e. the exclusive use of GO analysis by Moore and co-workers versus the combined use of GO, AFE, Swiss-Prot annotations, SignalP, and SecretomeP in our analysis, could account for the different numbers of proteins identified in two studies. Nonetheless, the data from both studies cross-validate each other while also being complementary.

Keene and co-workers also recently published a study in which they identified 169 putative astrocyte secreted proteins. They utilized Gel/LC-MS/MS, a method which is similar to 2D LC/LC-MS/MS, and a bioinformatics approach employing both a GO analysis and predictive secretion software (Protein Prowler and SecretomeP). When the list of secreted proteins from this study is compared against our list of secreted proteins, our study identified 101 out of the 155 secreted proteins identified by Keene and co-workers in their untreated control cultures, a 65% overlap in identifications. Again, this large degree of overlap between the studies strengthens the results of both studies. While the general experimental design of Keene and co-workers is very similar to ours, an important difference exists between the two studies—the length of media conditioning. Keene and co-workers collected conditioned media after both a single day and 7 days of incubation while we only collected media after a single day of conditioning. If only the protein identifications from the single day conditioned media are considered, 68 out of the 79 proteins that were identified by Keene and co-workers were also identified in our study—an 86% overlap. However, nine of the proteins identified solely by Keene and co-workers did not pass our AFE filter and thus may not be secreted. Additionally, our study identified over 100 proteins not identified in the single day conditioned media study from Keene and co-workers. This discrepancy is most likely due to the amount of starting material (we combined media from three separate T-25 flasks while they only combined media from two) and to the higher recovery and total protein identifications afforded 2D LC/LC-MS/MS separations versus 2D gel/LC-MS/MS (see Dowell et al. for a direct comparison of these techniques).46 However, the use of longer conditioning times (7 days) by Keene and co-workers resulted in the identification of 76 more proteins than identified in their single day experiments.

Clearly, the use of a cytoplasmic control increases confidence in the identification of secreted proteins and the use of multiple filters allows for greater flexibility in the downstream analysis. By changing the degree of filtering in our AFE analysis or GO/SecretomeP analysis, there is an increased confidence in the results (see Table 2). Applying a 3-fold AFE filter, results in a reduction of protein identifications from 262 to 167 and an increase in confidence. The additional application of the SecretomeP filter results in a further refinement of the results, yielding 123 secreted proteins versus our original 187 identifications. The use of multiple filters allows for the flexibility to strike a balance between confidence and comprehensiveness in the identification of secreted proteins.

Conclusions

The present study has identified 187 putative astrocyte secreted proteins using a combination of LC-MS/MS techniques, quantitative proteomics, and bioinformatics. Use of an integrated analysis regime incorporating multiple rounds of data refinement enables a flexible and robust analysis of secreted proteins.

Acknowledgements

We would like to thank Dr. Ying Ge and Matthew Lawrence of the University of Wisconsin Human Proteomics Program for access to the LC-MS/MS instrumentation and useful discussions. This work was funded by grants from the National Institutes of Environmental Health Sciences (ES08089 and ES10042 to JAJ). JAD was supported by a predoctoral training award from the American Foundation for Pharmaceutical Education (AFPE). LL acknowledges an Alfred P. Sloan Research Fellowship.

References

  • 1.Volterra A, Meldolesi J. Nat. Rev. Neurosci. 2005;8:626–640. doi: 10.1038/nrn1722. [DOI] [PubMed] [Google Scholar]
  • 2.Christopherson KS, Ullian EM, Stokes CC, Mullowney CE, Hell JW, Agah A, Lawler J, Mosher DF, Bornstein P, Barres BA. Cell. 2005;3:421–433. doi: 10.1016/j.cell.2004.12.020. [DOI] [PubMed] [Google Scholar]
  • 3.Chung RS, Hidalgo J, West AK. J. Neurochem. 2008;1:14–20. doi: 10.1111/j.1471-4159.2007.05026.x. [DOI] [PubMed] [Google Scholar]
  • 4.Dhandapani KM, Hadman M, De Sevilla L, Wade MF, Mahesh VB, Brann DW. J. Biol. Chem. 2003;44:43329–43339. doi: 10.1074/jbc.M305835200. [DOI] [PubMed] [Google Scholar]
  • 5.Lafon-Cazal M, Adjali O, Galeotti N, Poncet J, Jouin P, Homburger V, Bockaert J, Marin P. J. Biol. Chem. 2003;27:24438–24448. doi: 10.1074/jbc.M211980200. [DOI] [PubMed] [Google Scholar]
  • 6.Delcourt N, Jouin P, Poncet J, Demey E, Mauger E, Bockaert J, Marin P, Galeotti N. Mol. Cell. Proteomics. 2005;8:1085–1094. doi: 10.1074/mcp.M500040-MCP200. [DOI] [PubMed] [Google Scholar]
  • 7.Moore NH, Costa LG, Shaffer SA, Goodlett DR, Guizzetti M. J. Neurochem. 2009;108:891–908. doi: 10.1111/j.1471-4159.2008.05836.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Keene SD, Greco TM, Parastatidis I, Lee SH, Hughes EG, Balice-Gordon RJ, Speicher DW, Ischiropoulos H. Proteomics. 2009;9:768–782. doi: 10.1002/pmic.200800385. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Eddleston M, Mucke L. Neuroscience. 1993;1:15–36. doi: 10.1016/0306-4522(93)90380-X. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Nakagawa T, Schwartz JP. Neurochem. Int. 2004;2–3:203–242. doi: 10.1016/j.neuint.2003.09.007. [DOI] [PubMed] [Google Scholar]
  • 11.Wyss-Coray T, Mucke L. Neuron. 2002;3:419–432. doi: 10.1016/s0896-6273(02)00794-8. [DOI] [PubMed] [Google Scholar]
  • 12.Arendt T, Bruckner MK, Krell T, Pagliusi S, Kruska L, Heumann R. Neuroscience. 1995;3:647–659. doi: 10.1016/0306-4522(94)00523-8. [DOI] [PubMed] [Google Scholar]
  • 13.Dreyfus CF, Dai X, Lercher LD, Racey BR, Friedman WJ, Black IB. J. Neurosci. Res. 1999;1:1–7. doi: 10.1002/(SICI)1097-4547(19990401)56:1<1::AID-JNR1>3.0.CO;2-3. [DOI] [PubMed] [Google Scholar]
  • 14.Fiedorowicz A, Figiel I, Kaminska B, Zaremba M, Wilk S, Oderfeld-Nowak B. Brain Res. 2001;2:116–127. doi: 10.1016/s0006-8993(01)02675-0. [DOI] [PubMed] [Google Scholar]
  • 15.Knott C, Stern G, Kingsbury A, Welcher AA, Wilkin GP. Parkinsonism Relat. Disord. 2002;5:329–341. doi: 10.1016/s1353-8020(02)00008-1. [DOI] [PubMed] [Google Scholar]
  • 16.Bakhit C, Armanini M, Bennett GL, Wong WL, Hansen SE, Taylor R. Brain Res. 1991;1–2:76–83. doi: 10.1016/0006-8993(91)91217-o. [DOI] [PubMed] [Google Scholar]
  • 17.Shozuhara H, Onodera H, Katoh-Semba R, Kato K, Yamasaki Y, Kogure K. J. Neurochem. 1992;1:175–180. doi: 10.1111/j.1471-4159.1992.tb08888.x. [DOI] [PubMed] [Google Scholar]
  • 18.Bresjanac M, Antauer G. Exp. Neurol. 2000;1:53–59. doi: 10.1006/exnr.2000.7416. [DOI] [PubMed] [Google Scholar]
  • 19.Marco S, Canudas AM, Canals JM, Gavalda N, Perez-Navarro E, Alberch J. Exp. Neurol. 2002;2:243–252. doi: 10.1006/exnr.2001.7859. [DOI] [PubMed] [Google Scholar]
  • 20.Miyazaki H, Nagashima K, Okuma Y, Nomura Y. Brain Res. 2001;2:165–172. doi: 10.1016/s0006-8993(01)03013-x. [DOI] [PubMed] [Google Scholar]
  • 21.Buytaert KA, Kline AE, Montanez S, Likler E, Millar CJ, Hernandez TD. Brain Res. 2001;1:121–130. doi: 10.1016/s0006-8993(01)01987-4. [DOI] [PubMed] [Google Scholar]
  • 22.Ganat Y, Soni S, Chacon M, Schwartz ML, Vaccarino FM. Neuroscience. 2002;4:977–991. doi: 10.1016/s0306-4522(02)00060-x. [DOI] [PubMed] [Google Scholar]
  • 23.Acarin L, Gonzalez B, Castellano B. Eur. J. Neurosci. 2000;10:3505–3520. doi: 10.1046/j.1460-9568.2000.00226.x. [DOI] [PubMed] [Google Scholar]
  • 24.Friedman WJ. Exp. Neurol. 2001;1:23–31. doi: 10.1006/exnr.2000.7595. [DOI] [PubMed] [Google Scholar]
  • 25.Orzylowska O, Oderfeld-Nowak B, Zaremba M, Januszewski S, Mossakowski M. Neurosci. Lett. 1999;1:72–76. doi: 10.1016/s0304-3940(99)00043-9. [DOI] [PubMed] [Google Scholar]
  • 26.Mason JL, Suzuki K, Chaplin DD, Matsushima GK. J. Neurosci. 2001;18:7046–7052. doi: 10.1523/JNEUROSCI.21-18-07046.2001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Hulshof S, Montagne L, De Groot CJ, Van Der Valk P. Glia. 2002;1:24–35. doi: 10.1002/glia.10050. [DOI] [PubMed] [Google Scholar]
  • 28.De Groot CJ, Woodroofe MN. Prog. Brain Res. 2001;132:533–544. doi: 10.1016/s0079-6123(01)32101-5. [DOI] [PubMed] [Google Scholar]
  • 29.Pfrieger FW, Barres BA. Science. 1997;5332:1684–1687. doi: 10.1126/science.277.5332.1684. [DOI] [PubMed] [Google Scholar]
  • 30.Ullian EM, Sapperstein SK, Christopherson KS, Barres BA. Science. 2001;5504:657–661. doi: 10.1126/science.291.5504.657. [DOI] [PubMed] [Google Scholar]
  • 31.Adams JC. Annu. Rev. Cell Dev. Biol. 2001;17:25–51. doi: 10.1146/annurev.cellbio.17.1.25. [DOI] [PubMed] [Google Scholar]
  • 32.Stevens B, Allen NJ, Vazquez LE, Howell GR, Christopherson KS, Nouri N, Micheva KD, Mehalow AK, Huberman AD, Stafford B, Sher A, Litke AM, Lambris JD, Smith SJ, John SW, Barres BA. Cell. 2007;6:1164–1178. doi: 10.1016/j.cell.2007.10.036. [DOI] [PubMed] [Google Scholar]
  • 33.Chevallet M, Diemer H, Van Dorssealer A, Villiers C, Rabilloud T. Proteomics. 2007;11:1757–1770. doi: 10.1002/pmic.200601024. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Pellitteri-Hahn MC, Warren MC, Didier DN, Winkler EL, Mirza SP, Greene AS, Olivier M. J. Proteome Res. 2006;10:2861–2864. doi: 10.1021/pr060287k. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Kratchmarova I, Kalume DE, Blagoev B, Scherer PE, Podtelejnikov AV, Molina H, Bickel PE, Andersen JS, Fernandez MM, Bunkenborg J, Roepstorff P, Kristiansen K, Lodish HF, Mann M, Pandey A. Mol. Cell. Proteomics. 2002;3:213–222. doi: 10.1074/mcp.m200006-mcp200. [DOI] [PubMed] [Google Scholar]
  • 36.Zvonic S, Lefevre M, Kilroy G, Floyd ZE, DeLany JP, Kheterpal I, Gravois A, Dow R, White A, Wu X, Gimble JM. Mol. Cell. Proteomics. 2007;1:18–28. doi: 10.1074/mcp.M600217-MCP200. [DOI] [PubMed] [Google Scholar]
  • 37.Liu J, Hong Z, Ding J, Liu J, Zhang J, Chen S. J. Proteome Res. 2008;5:2033–2049. doi: 10.1021/pr7007779. [DOI] [PubMed] [Google Scholar]
  • 38.An E, Lu X, Flippin J, Devaney JM, Halligan B, Hoffman EP, Strunnikova N, Csaky K, Hathout Y. J. Proteome Res. 2006;10:2599–2610. doi: 10.1021/pr060121j. [DOI] [PubMed] [Google Scholar]
  • 39.Mbeunkui F, Fodstad O, Pannell LK. J. Proteome Res. 2006;4:899–906. doi: 10.1021/pr050375p. [DOI] [PubMed] [Google Scholar]
  • 40.Mbeunkui F, Metge BJ, Shevde LA, Pannell LK. J. Proteome Res. 2007;8:2993–3002. doi: 10.1021/pr060629m. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Kulasingam V, Diamandis EP. Mol. Cell. Proteomics. 2007;11:1997–2011. doi: 10.1074/mcp.M600465-MCP200. [DOI] [PubMed] [Google Scholar]
  • 42.Chen Y, Gu B, Wu S, Sun W, Ma S, Liu Y, Gao Y. J. Mass Spectrom. 2009;44:397–403. doi: 10.1002/jms.1517. [DOI] [PubMed] [Google Scholar]
  • 43.Lee JM, Calkins MJ, Chan K, Kan YW, Johnson JA. J. Biol. Chem. 2003;14:12029–12038. doi: 10.1074/jbc.M211558200. [DOI] [PubMed] [Google Scholar]
  • 44.Dennis G, Jr, Sherman BT, Hosack DA, Yang J, Gao W, Lane HC, Lempicki RA. Genome Biol. 2003;5:P3. [PubMed] [Google Scholar]
  • 45.Bendtsen JD, Nielsen H, von Heijne G, Brunak S. J. Mol. Biol. 2004;4:783–795. doi: 10.1016/j.jmb.2004.05.028. [DOI] [PubMed] [Google Scholar]
  • 46.Dowell JA, Frost DC, Zhang J, Li L. Anal. Chem. 2008;17:6715–6723. doi: 10.1021/ac8007994. [DOI] [PMC free article] [PubMed] [Google Scholar]

RESOURCES